翔宇医疗(688626) - 2024 Q1 - 季度财报

Financial Performance - The company's operating revenue for Q1 2024 was CNY 169,097,488.82, representing an increase of 18.12% compared to the same period last year[4]. - Net profit attributable to shareholders was CNY 39,073,828.52, reflecting a growth of 3.34% year-on-year[6]. - The net profit after deducting non-recurring gains and losses increased by 12.07% to CNY 36,482,745.51[4]. - Basic earnings per share rose by 4.17% to CNY 0.25, while diluted earnings per share increased by 8.33% to CNY 0.26[4]. - Total revenue for Q1 2024 was CNY 143,153,527.80, a decrease of 15.4% compared to CNY 169,097,488.82 in Q1 2023[19]. - Operating profit for Q1 2024 increased to CNY 44,155,701.28, compared to CNY 42,209,940.11 in Q1 2023, reflecting a growth of 4.6%[20]. - Net profit for Q1 2024 was CNY 38,592,209.22, slightly down from CNY 38,725,982.66 in Q1 2023, indicating a decrease of 0.3%[21]. - Earnings per share for Q1 2024 were CNY 0.24, compared to CNY 0.25 in Q1 2023, showing a decline of 4%[21]. - The company reported a net profit for Q1 2024 of CNY 35,128,486.74, a decrease of 13.5% from CNY 40,608,258.68 in Q1 2023[29]. Cash Flow and Assets - The net cash flow from operating activities decreased by 52.55% to CNY 17,295,631.36, primarily due to higher cash payments related to operating activities[6]. - The company's cash and cash equivalents decreased to CNY 287,015,000.00 in Q1 2024 from CNY 27,015,000.00 in Q1 2023, indicating a substantial increase of 964.5%[18]. - In Q1 2024, the company's operating cash inflow was CNY 175,052,571.80, a decrease of 4.1% from CNY 183,353,703.59 in Q1 2023[23]. - The total cash outflow from investment activities was CNY 184,905,943.42, significantly higher than CNY 335,845,061.28 in Q1 2023, resulting in a net cash flow from investment activities of -CNY 129,823,616.21[24]. - Cash inflow from financing activities reached CNY 267,000,000.00, compared to CNY 55,000,000.00 in Q1 2023, leading to a net cash flow from financing activities of CNY 205,139,626.91[24]. - The company's total assets as of March 31, 2024, were CNY 2,717,573,056.26, an increase from CNY 2,538,747,748.54 at the end of 2023[26]. - Current assets increased to CNY 1,339,973,202.13 from CNY 1,208,395,696.07 at the end of 2023, reflecting a growth of 10.9%[26]. - The company's cash and cash equivalents at the end of Q1 2024 were CNY 744,371,900.04, down from CNY 832,260,520.32 at the end of 2023[24]. - The total liabilities increased to CNY 701,249,031.21 from CNY 504,472,730.04 at the end of 2023, indicating a rise of 38.9%[27]. - The company's equity increased slightly to CNY 2,016,324,025.05 from CNY 2,034,275,018.50 at the end of 2023[27]. Research and Development - Research and development expenses totaled CNY 29,562,422.95, accounting for 17.48% of operating revenue, an increase of 2.39 percentage points[5]. - Research and development expenses for Q1 2024 were CNY 21,608,723.98, an increase of 0.3% from CNY 29,562,422.95 in Q1 2023[20]. - Research and development expenses increased to CNY 14,826,259.70 in Q1 2024, up from CNY 11,346,901.00 in Q1 2023, reflecting a growth of 30.5%[28]. - The company completed a project on "Key Technologies for Rehabilitation of Swallowing Disorders," which won the second prize in the China Industry-University-Research Cooperation Innovation and Promotion Award[12]. Corporate Developments - The company obtained 3 new medical device registration certificates, bringing the total to 321, and added 88 new patents, totaling 1,621 patents[11]. - The company signed an agreement with Xi'an Jiaotong University to establish a rehabilitation medical device research institute[11]. - The company was awarded the "2022 Key High-tech Enterprise Award" and recognized as a leading enterprise in digital transformation by the Henan Provincial Digital Economy Industry Association[11]. - The company’s intelligent rehabilitation equipment pilot base was included in the first batch of pilot base construction lists in Anyang City[11]. - The company’s smart lower limb feedback training system and other rehabilitation devices were included in the "Directory of Rehabilitation Aids (2023 Edition)"[11]. Inventory and Receivables - The company’s total inventory as of March 31, 2024, was RMB 243,465,927.15, slightly up from RMB 241,366,072.32[16]. - The company’s long-term receivables decreased to RMB 44,756,153.84 from RMB 45,622,848.01, a decline of about 1.9%[16]. - The company reported a significant increase in prepayments, which rose to CNY 173,061,636.86 from CNY 24,608,452.94 in the previous period[26].